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Introduction
Alzheimer’s Disease (AD), the most common form of dementia, is a neurodegenerative
disease characterized by a progressive loss of neural cells leading to nervous system dysfunction.
The hallmark signs are memory loss and decreased abilities to make judgements and perform
activities of daily living1 . Because of the increasing lifespan of humans, the projected number of
people 65 years and older diagnosed with AD is expected to reach 13.8 million by the year
20502 . Biologically, AD is characterized by deposition of beta-amyloid protein (Aβ) and tau
neurofibrillary tangles (NFTs). The deposition of Aβ occurs due to the cleavage of amyloid
precursor protein (APP) changing from α-secretase to β-secretase and γ-secretase. This change in
enzymatic activity causes larger Aβ molecules to form which then stack on top of one another
creating amyloid plaques3 . NFTs accumulate when isoforms of tau, a microtubule-associated
protein, begins to hyperphosphorylate and fold atypically1 . Over time, these accumulations of
amyloid plaques and NFTs lead to brain shrinkage and atrophy causing the well documented
signs of AD such as memory problems, impaired judgement, and personality changes1,4 .
AD is classified into two types, Familial Alzheimer’s Disease (FAD) and Sporadic
Alzheimer’s Disease (SAD). FAD, also known as early-onset AD, accounts for approximately
5% of all cases and occurs via genetic inheritance, beginning between the ages of 40 and 605 .
There are three genetic mutations that account for FAD, these are mutations in the genes that
encode for presenilin 1 (a subunit of γ-secretase), presenilin 2 (assist in processing APP), and
APP itself4 . SAD, or late-onset AD, typically occurs after the age of 65. It is not entirely
understood what causes SAD, but research indicates genetics, lifestyle, and environmental
factors, such as diet, disease state, age, socioeconomic status, and educational level, impact its
development5 .
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Hypotheses for AD development
Over the past several decades there have been many advances in AD research; however,
the cause is still unknown. Development of AD follows a well-documented path, known as
Braak staging. First described in 1991, Braak staging has six distinctive phases of AD grouped
into three units based on the location of NFTs. Stages I-II occurs in the transentorhinal and
entorhinal regions, III-IV are in the limbic allocortex and its adjacent neocortex, and V-VI are in
the neocortex6 . Once AD begins there is no reversing the disease; in order to better understand
the disease researchers have hypothesized over the causes of disease progression. The main
hypotheses include the amyloid, tau, oxidative stress, cholinergic, N-methyl-D-aspartate
(NMDA) receptor, and altered calcium homeostasis7-11 . More recently, impaired glucose
metabolism in the brain, pathogenic virus, and prion disease hypotheses have emerged as
possible causes of AD10,12,13 (Figure 1). Each of these pathways will be explored in more detail
but a brief description is included here. The amyloid and tau hypotheses are the most common as
the presence of amyloid plaques and NFTs are the definition of AD. The amyloid hypothesis
centers around the creation of amyloid plaques formed from longer sheets of Aβ 40-42 while the tau
hypothesis focuses on the accumulation of NFTs leading to neuron death7 . In oxidative stress,
neuronal hypoxia caused by an increase in reactive oxygen species (ROS) occurs7 . With the
cholinergic hypothesis, cholinergic function is lost leading to a decrease in the neurotransmitter
acetylcholine (ACh) and subsequent increases in cholinesterase 8 . At the NMDA receptor,
neuronal death occurs after excitotoxicity causes increased glutamate and decreased NMDA
receptors. The altered calcium homeostasis hypothesis focuses on altered mitochondrial function
due to changes in enzymatic activity. This decreased mitochondrial function causes defects in the
electron transport chain, leading to production and deposition of Aβ7 . More recently, high
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carbohydrate diets causing impaired glucose metabolism in the brain due to a decrease in
lipoprotein creation in the liver has been proposed as a possible mechanism of action10 . In 2018,
researchers proposed certain viruses, with emphasis on herpes simplex virus, have the ability to
stimulate the accumulation of Aβ12 . Lastly, prion disease, which occurs when the prion protein
causes normal proteins in the brain to misfold, is considered a possibility for AD development 14 .
This hypothesis centers around cellular prion protein (PrP C) acting as a cellular surface receptor
for Aβ13 .
AD and nutrition
Not only are researchers divided on the mechanism for AD development, but the research
into diet and its impact on these hypotheses is limited. A focus on the daily consumption of
complex carbohydrates; including vegetables, whole grains, fruit, nuts, seeds, and legumes has
been emphasized, with a strong correlation between adherence to a Mediterranean diet and
overall cognitive performance7,15 . One study reported that consumption of vegetables, fruits,
nuts, and fish were associated with improved subjective cognitive function when compared to the
intake of meat and dairy15 . A hybrid of the Mediterranean and Dietary Approach to Stop
Hypertension (DASH) diets, the Mediterranean-DASH intervention for Neurodegenerative
Delay (MIND) diet, has been developed to help delay the onset of cognitive decline16,17 . This
diet is high in nutrients that research has shown to slow cognitive decline and includes “…folate,
vitamin E, carotenoids, and flavonoids”16 . Therefore, an emphasis is placed on adding berries
and dark leafy greens, while not emphasizing large consumption of fruit, dairy, potato, and fish.
To date, studies have shown that a high adherence to the MIND diet may play a protective role
against AD development17 .
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Literature Review
1. Amyloid Hypothesis
The large majority of research surrounding diet and AD centers around the amyloid
hypothesis and the deposition of amyloid plaques. In healthy brains, α-secretase cleaves the vast
majority of APP, releasing shorter, harmless fragments of Aβ, such as Aβ 25 and Aβ38 . In the
brains of AD patients, β-secretase followed by γ-secretase, are highly active and cleave APP in
different locations, releasing longer Aβ proteins, like Aβ40 and Aβ42 18,19. Of these two longer
proteins, more Aβ40 is produced; however, Aβ42 is more toxic due to a higher affinity for
aggregating caused by its hydrophobic properties1 . Amyloid plaques are a buildup of these longer
Aβ sheets. Experiments have shown nutrients found in common foods can mitigate Aβ-induced
damage by increasing α-secretase, decreasing β-secretase and/or γ-secretase, disrupting amyloid
plaques, autophagy, and/or clearing Aβ across the blood brain barrier (BBB) (Figure 2)20-51 .
Specific nutrients reviewed to determine their effect on amyloid plaques were
docosahexaenoic acid (DHA), extra virgin olive oil (EVOO), resveratrol, curcumin,
epigallocatechin gallate (EGCG), salvianolic acid B (Sal B), and the fat-soluble vitamins, A, D,
E, and K. DHA is an omega-3 fatty acid that is anti-inflammatory and commonly found in
flaxseed oil, chia seeds, walnuts, and fish (among other things) 52 . EVOO, a cooking oil used
commonly in both the Mediterranean and MIND diets, is an unsaturated fat that contains various
isoforms of vitamin E as well as various phenolic compounds, flavonoids, and lignans 53 .
Resveratrol, a polyphenol found in nuts, berries, wine, and dark chocolate, has strong
antioxidant, anti-inflammatory, anti-cancer, and anti-ageing properties20 . Curcumin, a nutrient
found in turmeric, curry powder, and ginger, displays similar antioxidant, anti-inflammatory, and
anti-cancer properties as resveratrol21 . EGCG, a major polyphenol and catechin found in green
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tea has been shown to have neuroprotective effects22 . Sal B is a water-soluble derivative of
caffeic acid that has been commonly used in Chinese medicine to treat coronary artery disease
and cerebrovascular diseases54 . Lastly, multiple research studies have shown a positive
correlation between serum and plasma levels of fat-soluble vitamins and cognitive
performance55-68 . Interestingly, an association has also been found between individuals using a
vitamin K antagonist for their anticoagulant medication, such as Warfarin, and cognitive
impairment69 .
Activation of α-secretase
Compounds that have an ability to activate α-secretase would potentially be able to
increase the production of harmless Aβ leading to a decrease in the harmful Aβ23 . An in-vitro
study showed Neuroprotection D1 (NPD1), an enzymatic derivative of DHA, was shown to
activate α-secretase in a dose-dependent manner. In this study, overexpression of APP was
induced in aging human neuronal- glial cells through transient-transfection with Swedish
mutation APP. These cells were treated with NPD1 at concentrations of 0 nM, 50 nM, 100 nM,
and 500 nM, with the greatest effect seen at 500 nM23 . A second in-vitro study analyzed
resveratrol’s ability to upregulate sirtuin 1 (SIRT1), a silent information regulator that is
suppressed by Aβ(25–35). SIRT1 downregulates Rho-associated protein kinase 1 (ROCK1), an
inhibitor of α-secretase20 . This study incubated pheochromocytoma (PC12) cells with resveratrol
at concentrations of 12.5 μM, 25 μM, 50 μM, or 100 μM 2 hours prior to the addition of 20 μM
Aβ25-35 20. A significant increase of SIRT1 expression and a decrease in ROCK1 expression were
seen in western blot analysis showing the potential of resveratrol to upregulate α-secretase20 . An
in-vitro analysis looking into curcumins impact on human embryonic kidney cells (HEK293)
overexpressing APP. Curcumin, tetrahydrocurcumin (THC), curcumin-isoleucine (Cur-Ile),
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curcumin-phenylalanine (Cur-Phe), or curcumin- valine (Cur-Val) was added at a concentration
of 50 μM, with analysis showing Cur-Ile, Cur-Phe, and Cur-Val stimulated α-secretase
expression24 . A second in-vitro study on curcumin conducted on PC12 cells showed that lower
concentrations of curcumin were protective against Aβ-induced toxicity while higher
concentrations increased toxicity25 .
Decreased activity of β-secretase and/or γ-secretase
Through decreasing enzymatic activity of β-secretase and/or γ-secretase, the continued
production of harmful Aβ may decrease23 . An in-vitro study, looking at EGCG showed a 5minute incubation of green tea infusion inhibited β-secretase activity by as much as 27%, which
increased to 38% after 60 minutes26 . An in-vivo study utilizing an APP/Prresenilin-1 (PS1)
double-transgenic mouse study indicated EGCG was able to ameliorate learning and memory
impairment as seen in a Passive Avoidance Test and Morris Water Maze. Mice treated with
EGCG showed decreased concentrations of amyloid plaques, decreased concentrations of APP,
and decreased apoptosis of neurons with researchers proposing this activity being in part due t
EGCGs effects on γ-secretase70 .
When looking at in-vivo research, vitamin A deficiency has been shown to increase
deposition of Aβ in the brain and cerebral blood with supplementation of all-trans retinoic acid
improving cognitive function27 . One possible mechanism for this is through inhibiting βsecretase-dependent APP cleavage28 . In-vivo research into vitamin D has proposed a possible
mechanism for clearing Aβ is vitamin D’s ability to elevate neprilysin, an enzyme that is shown
to degrade Aβ and reduce concentrations of β-secretase29 . Studies into vitamin D have shown
significantly reduced amyloid plaques and improved cognitive performance with
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supplementation of a D3 enriched diet, although it is important to note that rats with normal
vitamin D levels did not show improvement in spatial performance with D3 supplementation29-32 .
Mechanisms by which vitamin E impacts AD include its effect on decreasing cholesterol
synthesis. Studies have shown a strong positive correlation between hypercholesterolemia and
Aβ production33 . The relationship between cholesterol and AD centers around cholesterol
increasing the activity of β- and γ- secretase34 . Because vitamin E is a group of eight compounds,
it can be confusing to know if it is a combination or just one of these isoforms that has the
greatest benefit. Table 1 breaks down some of the research into the various forms of vitamin E as
it relates to AD. Unfortunately, outcomes in human studies on vitamin E supplementation have
ranged from reduced need of care and slowed disease progression to no effect or an increased
cognitive decline35-38 .
Disruption of amyloid plaques
Causing a conformation change in amyloid plaques has shown potential for decreasing
overall amyloid load39-42,45 . An in-vitro analysis on resveratrol using PC12 cells showed 25 μM
resveratrol combined with 25 μM purified Aβ42 remodeled three Aβ42 conformers—soluble
oligomers, fibrillar intermediates, and amyloid fibrils—into an alternative aggregation that is
unstructured and nontoxic39 . This occurs due to resveratrol binding to the N-terminus of Aβ42
monomers, preventing the formation of oligomers longer than 1–2 nm. Similar results has been
seen in-vitro utilizing curcumin40 . In an in-vitro analysis, Sal B showed a significant inhibition of
the formation of Aβ42 that was both dose and time-dependent. Although a mechanism for how
Sal B inhibited Aβ42 was not proposed, researchers indicated fibrils of Aβ were converted into
deformed aggregates. Incubation with Sal B occurred up to 7 days with 100 μM concentrations 54 .
Additional In-vitro studies into vitamin K have indicated it has the potential to be an effective
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anti-amyloidogenic drug due to it inhibition of Aβ accumulation and toxicity through binding to
the Aβ monomer41 . Additionally, in-vitro analysis using human neuroblastoma cells (SH-S5Y5)
showed DHA interrupted the microenvironment of tyrosine in the Aβ42 backbone, thus reducing
levels of soluble Aβ42 oligomers and inhibiting the formation of Aβ42 fibrils. While 5 μM DHA
had no significant effect on fibril formation, 10 μM and 20 μM DHA decreased fibril formation
by 32% and 41%, respectively42 .
EGCG has shown the ability to decrease Aβ generation in a dose-dependent manner,
protect against Aβ-induced apoptosis, and inhibit fibrillization of Aβ22,43,44. A proposed
mechanism for how EGCG is able to do this is via covalent bonding with Aβ, preventing its
accumulation45 . It is important to note that EGCG is not the only catechin in green tea nor is it
the only antioxidant. It is likely the inhibition activity seen in the green tea infusion is due to the
cumulative effect of all of the bioactive compounds found in green tea. In one in-vivo study, αsecretase activity increased, overall plaque load was reduced by 50% and β-secretase and γsecretase activity decreased. Researchers concluded oral administration of EGCG was more
effective then injection24,43,46 .
Autophagy
Curcumin has also been shown to reduce Aβ42 toxicity through an in-vivo study
comparing the effects of curcumin supplementation in mice 47 . After sacrifice, control mice
showed well-formed amyloid plaques where treatment mice showed significantly reduced
plaques in a dose dependent manner in both the hippocampus and cortex47 . This same in-vivo
study showed an increase in autophagy of APP-rich organelles. Additionally, Morris water maze
test after six months of treatment with either control, low concentration, or high concentration of
curcumin revealed that mice completed the maze faster in a dose dependent manner. When the
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brains of the mice were extracted and analyzed it was determined that curcumin acts through the
PI3K/Akt/mTOR pathway to stimulate the autophagy of APP-rich organelles allowing for the
survival and proliferation of cells47 . Although in-vitro and in-vivo research has shown the benefit
of curcumin, two human studies, one a 6-month clinical trial and one a phase 2 double-blind
study did not show any improvement in cognitive performance or levels of amyloid plaques 48,49 .
This can potentially be caused by curcumin’s low bioavailability21 .
In one study on ambulatory AD patients, peripheral blood mononuclear cells (PBMCs)
were collected and differentiated into macrophages. These macrophages were incubated
overnight with either 1,25-dihydroxyvitamin D3 (1,25D3) at a final concentration of 0.01 to 0.1
μM or curcuminoids at a concentration of 0.001 μM to 1 μM. Fluorescently labeled Aβ was also
added, and fluorescence microscopy and enzyme- linked immunosorbent assay (ELISA) both
revealed that 1,25D3 increased clearance of Aβ through phagocytosis in all cells, and
curcuminoids significantly assisted in only 50% of cells. 1,25D3 stimulates transport of Aβ
within the cell, while curcuminoids stimulate surface binding. It was determined in silico that
1,25D3 binds to the genomic pocket of the vitamin D receptor (VDR), while curcuminoids binds
to the non-genomic pocket50 .
Clearing Aβ across the Blood Brain Barrier
One in-vivo study looking at the effects of EVOO on Aβ burden, showed after three and
six months of EVOO consumption, Aβ concentrations in mice brains were significantly reduced
by 24% and 29% respectively. Researchers found this reduction in Aβ load was possibly
associated with clearance across the blood brain barrier. Additionally, mice in the six-month
treatment group showed improvement in the burrowing and nest construction test compared to
control where mice in the three-month treatment group showed no improvement. Researchers
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proposed that clearing Aβ across the BBB could potentially prevent an accumulation of amyloid
plaques in the brain51 .
2. Tau Hypothesis
The Tau hypothesis for AD development goes hand in hand with Aβ accumulation; the
presence of both being the definitive diagnosis of AD7 . Tau proteins assist in the formation of
microtubules, promotion of microtubule stability, and synaptic plasticity. In the tau hypothesis,
NFTs are produced in the brain. This occurs through a chain reaction starting with tau protein
developing an unhealthy ratio of repeating amino acid sequences in the microtubule-binding
domain. A normal tau protein has around 77 serine/threonine sites that allow for phosphorylation
of the protein. When hyperphosphorylation occurs, tau’s affinity for microtubules is decreased
along with the overall stability of microtubules. As more tau proteins are hyperphosphorylated,
they accumulate, forming NFTs. This accumulation of NFTs leads to neuron death and cognitive
decline71 .
In-vitro studies have demonstrated that grape seed phenol extract, tannic acid, and
oleuropein (a compound found in olives) has the ability to inhibit the accumulation of tau by
breaking up preformed tau peptide aggregates and inhibiting their accumulation72-74 .
Additionally, in-vitro studies have shown grape seed phenol extract was able to breakdown
preformed tau peptides72 . In-vivo studies showed the effectiveness of grape seed phenol extract
at reducing the phosphorylation of tau and EGCG at suppressing phosphorylated tau
isoforms46,75,76 .
Similar to its effects on Aβ plaques, vitamins A and E have shown the potential to reduce
the concentration of NFTs. Vitamin A shows this activity with supplementation of all-trans
retinoic acid in in-vivo studies and is possibly due to retinoic acid’s ability to prevent tau
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phosphorylation27,77,78 . Vitamin E shows this action via trolox, an analog of vitamin E that is
water soluble79 . A second in-vivo study showed supplementation with α-tocopherol caused
suppressed development of NFTs80 .
3. Oxidative Stress
During oxidative stress, there is an imbalance between the production of ROS and their
clearance from the body. As a result, neuronal hypoxia may occur, leading to neurodegeneration.
Because the brain is more susceptible to free radical damage then other organs, oxidative damage
can be both a potential cause of and result of Aβ deposition. The amyloid and oxidative stress
hypotheses are closely linked due to APP and its derivatives causing excessive generation of
ROS in mitochondria. This, coupled with oxidative stress, potentially causing increases in βsecretase and γ-secretase, leading to increased plaque deposition7 .
ROS play a pivotal role in immune response and cell signaling and are created during
normal physiological processes. In a healthy individual, endogenous antioxidant defense systems
keep ROS at healthy levels7 . Various mechanisms are known to increase the levels of ROS in the
brains of patients with AD, including increasing amyloid plaque load and increasing
excitotoxicity from the NMDA receptor81-83 . In order to maintain a healthy equilibrium between
creation and degradation of ROS, a diet high in antioxidants is crucial7 . Antioxidants scavenge
ROS and inhibit their continued formation. By including antioxidants in the diet, they increase
the effects of endogenous antioxidants84 .
Many vitamins, minerals, and polyphenols display antioxidant activity, including
vitamins A, C, and E; selenium; and polyphenols such as resveratrol85 . Antioxidants are
primarily found in plant-based foods, such as teas, nuts, berries, dark chocolate, and fruit81 . Due
to the importance of antioxidants, the creators of the MIND diet emphasized consumption of
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complex carbohydrates. The MIND diet includes ten categories of brain healthy foods (“…green
leafy vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive oil,
and wine…”) and five categories of unhealthy foods (“…red meats, butter and stick margarine,
cheese, pastries and sweets, and fried/fast foods…”)16 . In one study of preclinical AD patients,
the MIND diet was significantly associated with a decreased risk of developing AD. Individuals
in the highest quartile of compliance had a 53% reduction in AD compared to the lowest
quartile17 .
Resveratrol can also act in combination with melatonin to attenuate oxidative stress
associated with Aβ42. An in-vitro study using HT22 hippocampal cells determined Aβ1-42
induced cell death via oxidative stress in a dose dependent manner. Researchers measured levels
of ROS as well as cell viability to show the effects of Aβ 1-42 without treatment groups. The cell
line was infected with 2 μM Aβ1-42 and treated with 0.1 μM to 20 μM resveratrol and/or 1 μM to
500 μM melatonin. Using DCF fluorescence, it was determined that the maximum reduction of
oxidative stress was achieved at concentrations of 20 μM resveratrol and 500 μM melatonin, and
that co-treatment revealed synergistic effects. Spectrophotometry revealed that resveratrol and
melatonin may reduce oxidative stress by preventing the depletion of glutathione, another
antioxidant. Aβ treatment resulted in a glutathione decrease of 20%, and the addition of
resveratrol and melatonin increased glutathione to at least control levels86 . Another in-vitro study
conducted rat primary cortex neurons using resveratrol as well as two other stilbenes, trans-4hydroxystilbene (THS) and trans-3’4’,3,5-tetrahydroxy-stilbene (PIC) showed the free radical
scavenging ability of these compounds. THS showed the lowest effectiveness on ROS at 6.25%,
followed by resveratrol at 13.07% and PIC at 26.82%. When compared with Aβ25-35 , stilbenes
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showed a significant dose-dependent decrease in ROS showing a possible neuroprotective effect
of these nutraceuticals87 .
Cocoa extract is another high antioxidant/high polyphenol compound that can reduce the
oligomer formation of Aβ42. In the presence of equimolar cocoa extracts, dimers, pentamers,
and hexamers of Aβ42 were not formed while trimers and tetramers were greatly reduced. When
looking at Aβ40 similar decreases were seen; trimers and tetramers were completely blocked by
Levado extract and reduced by natural and Dutch cocoa extracts while dimers were reduced by
Levado, natural, and Dutch cocoa extracts88 . A second in-vitro study looked at supplementation
of cocoa extract and its protection from Aβ cytotoxicity due to oxidative stress. Researchers
found the toxicity was attenuated and cell viability was increased with treatment of cocoa
extract89 .
Lycopene, found in tomatoes and tomato products, is a carotenoid with strong
neuroprotective, antioxidant, and anti-inflammatory activity. Lycopene is also studied due to its
ability to cross the blood brain barrier and to specifically act as an antioxidant in the brain. One
in-vitro study pre-treated primary cultured cortical neurons with lycopene, followed by Aβ 25-35 .
Although researchers utilized the shorter, less toxic form of Aβ , they stated the peptide utilized in
their experiments is shown to “…retain the toxicity of the full length Aβ…”90 . What researchers
found was the pre-treatment of lycopene significantly protected against neurotoxicity by
reducing apoptosis and decreasing concentrations of ROS’s in a dose dependent manner 90 .
4. Cholinergic Hypothesis
The cholinergic hypothesis of AD is based on ACh, the major neurotransmitter within the
cholinergic system, playing an important role in memory and learning7 . ACh synthesis occurs in
the presynaptic nerve terminal and is the byproduct of the enzyme choline acetyltransferase on
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Acetyl Coenzyme A (Acetyl CoA) and choline. After ACh is synthesized, it is released into the
synaptic cleft where it attaches to presynaptic and postsynaptic receptors, which in turn regulates
both neurotransmission and further release of ACh. At this point ACh is broken down by
acetylcholinesterase (AChE) into acetate and choline which go back into circulation to produce
additional ACh91 . During the development of AD (as well as in the ageing process), a loss of
cholinergic function in the central nervous system (CNS) occurs and is associated with a
measurable decrease in the amount of ACh and an increase in total cholinesterase in the brain7,92 .
This loss of ACh is hypothesized to contribute to cognitive decline7 . Currently, the majority of
pharmacological treatments for AD focus on AChE inhibition in order to slow down the
breakdown of ACh which subsequently causes an increase in synaptic concentration of ACh as
well as its neurotransmission regulatory effects. At this time, AChE inhibitors offer only modest,
short-term relief during the early stages of cognitive decline 91 .
Butyrylcholinesterase (BuChE) is a second neurotransmitter within the cholinergic
system that is important in cholinergic neurotransmission regulation as well as the development
of the nervous system8 . In 41-80% of patients with advanced AD, BuChE activity is significantly
enhanced while AChE is decreased by 10-60% in the area of amyloid plaques and NFTs.
Traditional treatment for AD targets AChE in order to prevent the breakdown of ACh, which
delays the onset of AD but does not stop the progression of the disease8 . Interestingly, when
BuChE is inhibited, a dose-dependent increase of ACh is seen in the brain with BuChE
remaining unaffected by increasing concentrations of ACh91 . See Table 2 for examples of dietary
components that may play a role in the cholinergic hypothesis for AD development.
5. NMDA Receptor
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NMDA receptors plays an important role in short and long-term memory, synaptic
plasticity, and learning. When overstimulated it can produce free radicals and cause cognitive
defects through neuron death7,93 . NMDA receptor is a glutamate receptor that can either be
bound to glutamate (an excitatory neurotransmitter) or glycine (an allosteric modulator)93 . In
normal conditions, glutamate homeostasis prevents the overaccumulation of glutamate.
Additionally, NMDA receptors are highly sensitive with regulation occurring via PrP C. Higher
concentrations of PrPC reduces the expression of NMDA receptors. During the pathogenesis of
AD, increasing concentrations of Aβ in the brain causes overstimulation of glutamate,
simultaneously Aβ binds to PrPC, removing its inhibitory role on NMDA receptor causing its
concentration to increase. Excitotoxicity then causes the production of ROS, leading to neuron
death, cognitive dysfunction, and ultimately AD94 .
Simultaneously, excitotoxicity causes an influx of calcium through the NMDA receptor
which disrupts learning and memory and causes death to the cell7,94 . In one study, walnuts were
found to simultaneously increase NMDA receptor activity while decreasing excitotoxicity95 .
Researchers believed it was the combination of polyunsaturated fatty acids, antioxidants, and
polyphenols found in walnuts that provided this neuroprotective effect as seen through
decreasing concentrations of lipid peroxidation95 . Similarly, another study looking at
supplementation of vitamin D in rats found that rats consuming vitamin D had an increase in the
expression of NMDA receptors which was positively associated with cognitive function96 .
Research into the effects of vitamin E on NMDA receptors has also been conducted. Invitro research on mouse embryonic stem cells induced toxicity of glutmate followed by treatment
with either α-tocopherol or tocotrienol rich fraction (TRF) which was composed of 25%
tocopherol and 75% tocotrienol. This post treatment of cells with vitamin E was conducted in
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order to assess the neurorecovery properties of vitamin E against glutamate toxicity. Researchers
found posttreatment with α-tocopherol and TRF reduced cell death in a dose-dependent manner
with TRF having a greater effect then α-tocopherol alone. This increase in cell viability occurred
due to α-tocopherol and TRF acting as antioxidants and reducing levels of ROS 82 .
6. Altered Calcium Homeostasis
Research into mitochondrial health has indicated that as we age the function of the
mitochondria declines. This is important because the mitocho ndria are not only the site where
bodies produce the majority of ATP for energy, but they also assist in maintaining calcium
homeostasis7 . Research has shown a decrease in mitochondrial function in AD patients within
brain, fibroblasts, and blood cells97,98 . Mitochondria dysfunction begins with a reduction in
enzymatic activity within the mitochondria. This leads to defects in the electron transport chain,
altered calcium homeostasis, and eventually AD due to increasing the likelihood of Aβ
production and deposition7 .
Effect of nutraceuticals on mitochondria
The composition of lipids in the mitochondrial membrane changes with age. One study
suggests that as people grow older, the percentage of phospholipids containing DHA in the
mitochondrial membrane increases99 . The ability of mitochondrial membranes to change lipid
composition as a result of a change in diet has been demonstrated in 8-month-old zebrafish,
whose mitochondrial membranes contained a higher percentage of DHA after a diet high in
DHA100 . The same effect was found in eicosapentaenoic acid (EPA), another omega-3 fatty
acid101 ; although additional research suggests that while DHA and EPA exhibit many similar
biological effects, research has indicated that EPA, but not DHA, improved protein quality in
mitochondria and mitigated loss of mitochondrial function in aged mice 102 . One human study
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showed a substantial reduction in the risk of all-cause dementia for individuals who were in the
highest quartile of plasma DHA levels103 .
Resveratrol (as an antioxidant) has been found to pick up electrons that have been leaked
from the respiratory chain, increase the formation of antioxidant species, and participate in
mitochondrial energy biogenesis104 . One study showed resveratrol increased cell survival by
mitigating the levels of ROS in the mitochondria, although the same study suggested that
resveratrol increases the total amount of ROS in the cell83 . As stated previously, resveratrol
activates SIRT1, which in addition to its anti-amyloid properties, regulates mitochondria
function and energy metabolism105 . Several polyphenols, including resveratrol, were found to
affect mitochondrial biogenesis by upregulating the promoter of mitochondrial transcription
factor A (Tfam)106 . Other studies, however, suggest resveratrol actually induces apoptosis by
upregulating the release of cytochrome c from the mitochondria, and increasing the expression of
proapoptotic proteins while downregulating antiapoptotic proteins

107 .

Like resveratrol, curcumin is an antioxidant that has demonstrated neuroprotective effects
by mitigating oxidative stress caused by mitochondrial dysfunction108 . In the kidneys of diabetic
mice, curcumin also protects mitochondria from the effects of hyperglycemia by modifying
oxygen consumption rate, nitric oxide synthesis, and the levels of thiobarbituric acid-reactive
substances (TBARS)109 . A hybrid compound of curcumin and melatonin has been found to
upregulate the expression of complexes I, II, and IV of the electron transport chain in
mitochondria in the brain tissue of APP/PS1 mice 110 . Experiments with cancer cells in-vivo and
adipocytes in-vitro have suggested that curcumin, as well as several derivatives, including
bisdemethoxycurcumin (BDMC), can induce apoptosis by inducing the release of cytochrome c

18
from the mitochondria111,112 . In contrast, a study using diabetic rat testicular cells has suggested
that curcumin protects against mitochondria-dependent apoptosis113 .
In an in-vitro study, researchers indicated that vitamin D downregulates respiratory chain
transcription in these cells and upregulates biosynthetic pathways instead, thus increasing cell
growth and proliferation114 . A similar study indicated vitamin D acts as a gatekeeper for the
mitochondrial respiratory chain by suppressing the transcription of cytochrome c oxidase
subunits II and IV. This downregulates the Krebs cycle and directs the cell toward biosynthetic
pathways115 . Interestingly, vitamin D receptors can be transferred from the nucleus to the
mitochondria which would help to increase the biosynthetic pathways116 .
One in-vivo study on lycopene injected rats with Aβ42 and observed how treatment with
lycopene at doses of 1, 2, and 4 mg/kg orally impacted their mitochondrial activity. What
researchers found was a significant increase in mitochondrial complex enzyme (I, II, and IV) in
both the cerebral cortex and hippocampus along with a significant restoration of mitochondrial
redox activity. Additionally, lycopene treated rats performed better then control in a Morris
water maze test117 .
A high-resolution respirometry system revealed Aβ and tau may work synergistically to
reduce the oxidative phosphorylation capacity of mitochondria through chronic oxidative
stress118 . It has also been suggested that Aβ derived from the endoplasmic reticulum (ER), Golgi
apparatus, or mitochondria-associates ER membranes (MAM) accumulates in the mitochondria,
which disrupts Ca2+ homeostasis and increases the production of free radicals 119 . The above
listed research into the effect of nutraceuticals on apoptosis has been conducted murine muscle
cells, breast and gastric cancer cells, human adipocytes, diabetic rats with testicular
abnormalities, and human proliferating keratinocytescells 106,107,111-115. The variety of cell types
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used can possibly explain some of the opposing effects seen in resveratrol and curcumin (Figure
3).
7. Impaired Glucose Metabolism
A more recent hypothesis on the development of AD is it is caused by impaired glucose
metabolism in the brain. Individuals diagnosed with type 2 diabetes in their mid-life as opposed
to later in life are 1.5 times more likely to develop AD. Brain glucose hypometabolism can be
detected through tomography imaging and is proposed as a possible tool for early diagnosis of
AD. This link between glucose hypometabolism and AD development focuses on diets that are
high in carbohydrates (with an emphasis on fructose and fructose-containing carbohydrates),
inhibiting the liver from creating lipoproteins. This decrease in lipoprotein formation starve
neurons of these nutrients causing the cascade effect of neurodegeneration10 . One study showed
a negative correlation between glycemic load dietary pattern and overall cognition and
performance on various neuropsychometric tests120 .
In one in-vitro study, cultured rat hippocampal cells were exposed to Aβ42, causing a
reduction in the number of cells and neurite length. For cells simultaneously exposed to βhydroxybutyrate (a ketone body) they doubled the number of surviving cells and increased
neurite overgrowth121 . In two in-vivo studies, a ketogenic diet was found to reduce the overall
volume of formed Aβ with one showing decreased concentrations of NFTs and improved
cognitive function122,123 . In one human study, 15 participants maintained a ketogenic diet with
medium chain triglyceride (MCT) oil supplementation. In participants who maintained ketosis, a
significant improvement in the AD Assessment Scale cognitive subscale score was observed.
After participants returned to their previous diet their cognitive functions returned to baseline 124 .
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One case study placed the participant on a ketogenic diet along with high intensity
interval training (HIIT) until ketosis was reached. After sustained ketosis their Hemoglobin A1C
was within normal limits and an improvement in spatial awareness and self-efficacy was evident
each week125 . A second case study had a patient consume a ketogenic and calorie restricted diet
in addition to HIIT exercises. This patient entered ketosis within three weeks and saw a 26%
increase in memory function score from baseline 126 .
8. Pathogenic Viral
The pathogenic viral hypothesis on AD progression is fairly new, with research
conducted in 2018 suggesting certain viruses, like herpes simplex virus, may be responsible for
the long and slow progression of AD12 . Research had previously indicated that microbes are able
to stimulate the formation of Aβ as a defense mechanism to stop the infectious process127 . In
genetic analysis, researchers found differential gene expression associated with various viruses
like Epstein-Barr virus (EBV) and human herpesvirus 6A (HHV-6A) and sought to determine if
patients diagnosed with AD showed genetic changes caused by viruses. What researchers found
was an increased quantity of HHV-6A and human herpesvirus 7 (HHV-7) in the brains of
patients who had passed away from AD12 . Conducting a quick PubMed review of herpes simplex
virus & diet brings up 58 articles but research into the way diet can reduce the impact of herpes
simplex virus is lacking.
9. Prion Disease
In the prion disease hypothesis, Aβ oligomers bind to PrPc receptors on neurons and
initiate signaling transduction pathways that ultimately lead to neuronal death128-131 . In-vitro
analysis has indicated PrP c is capable of mediating the toxic effects of Aβ due to Aβ42 having a
high affinity for PrPc132 . Subsequent in-vivo analysis determined PrPc was essential for the
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toxicity caused by Aβ and mice lacking PrPc who had amyloid plaques showed no spatial
learning or memory impairment133 . When conducting a PubMed review of PrP c associated with
AD and diet only three articles came back 134-136. None of these articles discussed the impact diet
has on the development of AD via prion disease.
Summary
In 1906, Dr. Alois Alzheimer first described amyloid plaques and NFTs137 . What has
become clear since that time is AD is more confusing then researchers initially imagined. In this
paper, a discussion was had on some of the more popular hypotheses surrounding AD
development, many of which are hard to distinguish from each other due to their similarities.
Between the amyloid, tau, oxidative stress, cholinergic, NMDA, altered calcium homeostasis,
impaired glucose metabolism in the brain, pathogenic virus, and prion disease hypotheses it
becomes apparent how interconnected many of them are. For instance, does the generation of
amyloid plaques cause ROS to form or does oxidative stress form ROS leading to the
development of amyloid plaques? With all of the compelling research on the nine potential
pathways it becomes apparent that AD likely utilizes multiple pathways simultaneously, creating
some type of interconnected loop.
Even more confusing than the cause of AD, is the role that diet plays on protecting
humans from developing it. Human studies on diet and AD are limited and typically occur after
an individual is already displaying signs of cognitive dysfunction35-38,48,49,103,124-126. At that point
in time, all of the research is focused on slowing the pace of cognitive decline because of AD’s
irreversible nature. Many of the bioactive compounds found commonly in plants, such as
walnuts, berries, and dark leafy greens, can potentially modulate the formation of AD in multiple
ways. Through this research we’ve learned the importance of antioxidants to remove ROS and
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decrease amyloid load by targeting the various enzymes in the accumulation of amyloid plaques.
Although the large majority of studies are looking at how diet impacts AD after it has already
begun, the question remains, what is the right diet for a prolonged healthy life? While the
evidence points towards the Mediterranean diet as an excellent option for long term health, does
the MIND diet help slow the rate of cognitive decline once AD has started? What these diets
have in common is a high consumption of antioxidant, anti-inflammatory, whole plant-based
foods. Consuming these foods, like EVOO and resveratrol may help the body fight AD by
decreasing the amount of ROS, keeping the mitochondria healthy, and reducing the potential
build-up of amyloid plaques. One human study analyzed dietary patterns in patients over the
course of 3.9 years and compared it to their degree of AD risk. What researchers found was a
dietary pattern that was significantly associated with reduced risk of AD. It was also positively
correlated with consumption of “…salad dressing, nuts, fish, tomatoes, poultry, cruciferous
vegetables, fruits and dark and green leafy vegetables…” and negatively correlated with a
consumption of “…high-fat dairy, red meat, organ meat, and butter…”138 .
Looking forward, research needs to focus more on all of the lifestyle factors that
contribute to AD. A question remains about whether individuals genetically predisposed to AD
can impact its development through modifying their lifestyle. Garcia-Escudero et al and Weuve
et al have written about how not only diet, but disease state, age, socioeconomic status, and
educational level all impact the development of AD5 . African Americans are 2-3 times more
likely than whites to have cognitive impairment as they age139 . In fact, one study showed that
stress over the course of your lifetime is associated with decreased cognition later in life with
African Americans reporting higher stressful events in their lives 140 . In addition, a quick search
of K-12 nutrition education programs shows that nutrition education comes from after school
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programs and the school nutrition program, who is responsible for providing meals to children.
From a nutritional standpoint it is easy to emphasis consuming a diet that is high in antioxidant,
anti-inflammatory, whole foods; however, before recommending this, it is important to recognize
what the possible barriers are to an individual getting what they need. Knowing whether they live
in a food desert, what their financial/transportation situation is, and what education they have
received about eating healthy can lead the conversation. In the previous study linking dietary
patterns with risk of AD, the population consuming the diet with the lowest risk of AD tended to
be younger, more educated, non-current smokers141 . Future research needs to focus on bringing
nutrition education to everyone and reducing the health disparities. Through incorporating
education in the classrooms from a young age, a longitudinal study could show us the impact of a
low-risk AD healthy diet throughout the life instead of focusing on preventing the further
development of a disease that currently has no cure.
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Figure 1: Summary of hypothesis leading to the development of Alzheimer’s Disease.

Aβ: beta-amyloid protein; ROS: reactive oxygen species; ETC: electron transport chain; ACh: Acetylcholine; TChE: Total
Cholinesterase; CNS: Central Nervous System: NMDA: N-methyl-d-aspartate
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Figure 2: Effects of diet on the amyloid hypothesis of Alzheimer’s Disease development

Adapted from Rosenberg, et al18 . DHA: docosahexaenoic acid; EGCG: epigallocatechin gallate;
EVOO: extra virgin olive oil
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Table 1: Summary of research into the impact of vitamin E isoforms on the amyloid hypothesis.
α-tocopherol
• Higher intake associated with reduced AD risk 62-64
• If γ-tocopherol levels are low, higher α-tocopherol levels are
associated with higher Aβ load64
• In-vivo study showed dietary supplementation along with Nacetylcysteine and alpha-lipoic acid prevented cognitive decline142
• α-tocopherol quinine is an oxidative metabolite of α-tocopherol and
has been shown to improve memory in in-vitro studies143
• α-tocopherol + α-tocopherol quinine shown to decrease Aβ
accumulation and toxicity142
γ-tocopherol
• Higher plasma levels associated with lowered AD neuropathology144
• One in-vitro study showed increased Aβ secretion with treatment due
to increased expression of β- and γ- secretase145
δ -tocopherol
• One in-vitro study showed increased Aβ secretion with treatment due
to increased expression of β- and γ-secretase145
α-tocopherol +
• In-vitro analysis indicates it disrupts formation of Aβ42146
α-, β-, γ-, δ• In-vivo analysis indicated an improvement in cognitive impairment
tocotrienol
and a decrease in Aβ deposition with supplementation146
supplement
AD: Alzheimer’s Disease; Aβ: beta-amyloid protein
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Table 2: Summary of research into dietary nutrients impact on the cholinergic hypothesis.
Alkaloids
Largest group of metabolites with ChE inhibitory activity at lower concentrations.
Examples include physostigmine which decreases AChE but not BuChE and
berberine, an isoquinoline alkaloid that inhibits ChEs and β-secretase activity in
rabbits, and galantamine8
Brava Oil
Showed dose dependent inhibition of BuChE and AChE147
Coumarins
Display AChE inhibition with some showing good BuChE inhibition8
Flavonoids
Along with isoflavones have higher AChE activity. The number of hydroxyl
groups on the B ring of a flavonoid influences the potency of BuChE inhibition
with an increase in the number of hydroxyl groups decreasing BuChE inhibition.
Examples include Galangin, a type of flavanol had strong anti-ChE activity with
the most potent activity against BuChE8
Lycopene
In-vivo study showed reversal of AChE activity and improved performance on
Morris water maze test117
Mansa Oil
Showed dose dependent inhibition of BuChE but not AChE147
Prenyltransferase
Have been used to rescue synaptic and cognitive deficits caused by overactivation
Inhibitors
of farnesylated proteins. GGTIs can act directly on neuronal cells and the CNS 148
Quinones
Pro-oxidants needed for mitochondria respiration. Redox reactions may occur
creating semiquinones and hydroquinones which can create additional ROS. Some
also work as AChEi8
Spanish Sage
Inhibit AChE, is an antioxidant, anti-inflammatory, and displays estrogenic
effects. Estrogenic agents are potentially protective in preventing or delaying
neurodegeneration in AD149
Stilbenes
Secondary metabolites derived from phenylpropanoid pathway and includes
Resveratrol. Stilbenes other than resveratrol (like Gnetol) have better AChE and
BuChEi activity8
Terpenic
Built up from isoprene subunits and are the most numerous and structurally
Compounds
diverse group of secondary metabolites produced by plants. It takes higher
concentrations of terpenes to inhibit ChE. Dihydrotanshinone and
cryptotanshinone have the potential to cross the BBB8
Tocotrienols
Tocotrienols appear to be superior to tocopherols because of their better
distribution in the fatty layers of the cell membrane. Overall reduces free radical
markers decreases AChE150
Xanthones
Secondary metabolites produced by plants, fungi, and lichens. Generally weak
ChE inhibitors but with a lipophilic side chain it improves 8
Vitamin A
In-vivo studies indicate restored AChE activity with supplementation of all-trans
retinoic acid151
AChE: Acetylcholinesterase; AChEi: Acetylcholinesterase inhibitor; AD: Alzheimer’s Disease; BBB:
Blood Brain Barrier; BuChE: Butyrylcholinesterase; BuChEi: Butyrylcholinesterase inhibitor; ChE:
Cholinesterase;: GGTIs: Geranylgeranyl Transferase Inhibitor; ROS: Reactive Oxygen Species
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Figure 3: Cell type dependent effect of nutraceuticals on apoptosis

Curcumin and resveratrol have shown opposing effects on mitochondria apoptosis depending on
cell type. Vitamin D on the other hand has been shown to increase apoptosis.
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